The Role of HSD3B1 in Prostate Cancer Progression and Treatment
/in Observational, Retrospective studies/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/in Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial for a New PSMA Radioligand 177Lu‑PSMA‑VG01 June 25, 2026
- Darolutamide Versus Abiraterone-Based Triplets in mHSPC: Real-World Signals from the ARON-3 Study June 25, 2026
- A New Clue for Prostate Cancer Survival June 23, 2026
- Newsletter 25/2026 June 21, 2026